Loading
A phase 3 trial testing YL202 in HR-positive / HER2-negative breast cancer, now recruiting.
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer is a phase 3 interventional study registered as NCT07461454, led by MediLink Therapeutics (Suzhou), and recruiting on the registry. Official title: A Randomised, Open-label, Multicenter, Phase 3 Study of YL202 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy. Planned enrolment is 376 participants (estimated). The study started in 2026-03-17 and primary completion is expected in 2027-12-31. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares YL202, MediLink Therapeutics.
Shares YL202, MediLink Therapeutics.
Shares YL202, MediLink Therapeutics.
Shares YL202, MediLink Therapeutics.
Shares YL202, MediLink Therapeutics.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/